8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 24, 2026·SEC
Material company update
Mar 3, 2026·SEC
Amylyx Pharmaceuticals, Inc.(AMLX)Earnings, Financials & Key Ratios
AMLX•NASDAQ
$17.79
Price updated Jun 27, 2026
AboutAmylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.Show more
- Revenue$0-100.0%
- EBITDA-$153M+51.3%
- Net Income-$145M+52.0%
- EPS (Diluted)-1.53+65.5%
- ROE-61.59%+39.0%
AMLX Price & Volume
Amylyx Pharmaceuticals, Inc. (AMLX) stock price & volume — 10-year historical chart
Loading chart...
Clinical Pivot Follows Total Commercial Revenue Erasure
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial Position:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
"Amylyx Pharmaceuticals is currently navigating a high-risk transition to a clinical-stage entity following the voluntary withdrawal of Relyvrio, which resulted in a complete cessation of commercial revenue. The company's future hinges on the success of its pipeline, yet it faces significant pressure as quarterly operating losses consistently exceed $35 million. Investors should monitor the sustainability of the $229.1 million cash position, which must support ongoing R&D expenses of approximately $27.6 million per quarter without the benefit of product sales."
Verdict Logic
the company lacks any active commercial revenue streams to offset its $27.6 million quarterly R&D burn rate, creating a precarious liquidity profile that warrants extreme caution.
AMLX Growth Metrics
Amylyx Pharmaceuticals, Inc. (AMLX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM100%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM31.41%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM52.41%
Return on Capital
10 Years-308.81%
5 Years-85.29%
3 Years-53.12%
Last Year-64.52%
AMLX Recent Earnings
Amylyx Pharmaceuticals, Inc. (AMLX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 4/12 qtrs (33%)●Beat Revenue 2/12 qtrs (40%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.37-8.8%
$0.34
Rev
—
—
Q2 2026
Mar 3, 2026Metric
Actual
Est
EPS
$0.30+3.2%
$0.31
Rev
—
$52,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.37+14.0%
$0.43
Rev
—
$52,000
Q3 2025
Aug 7, 2025Metric
Actual
Est
EPS
$0.46-4.5%
$0.44
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.37vs $0.34-8.8% | — |
| Q2 2026 | Mar 3, 2026 | $0.30vs $0.31+3.2% | —vs $52,000 |
| Q4 2025 | Nov 6, 2025 | $0.37vs $0.43+14.0% | —vs $52,000 |
| Q3 2025 | Aug 7, 2025 | $0.46vs $0.44-4.5% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Amylyx Pharmaceuticals, Inc. (AMLX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $17.79 | $1.48B | -11.63 | -100% | — | -61.59% | — | |
| $81.18 | $13.42B | -34.11 | 33.87% | -30.87% | -58.57% | — | |
| $216.03 | $31.89B | 24.47 | 1.39% | 13.92% | 7.55% | — | |
| $512.65 | $11.82B | -39.89 | 432.05% | -27.32% | -50.15% | — | |
| $25.32 | $4.34B | 11.06 | 11.87% | 34.3% | 35.65% | — | |
| $10.02 | $524.58M | -2.21 | -92.84% | -260.92% | -49.88% | — |
Compare AMLX vs Peers
Amylyx Pharmaceuticals, Inc. (AMLX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
AMLX SEC Filings & Documents
Amylyx Pharmaceuticals, Inc. (AMLX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when AMLX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
AMLX Frequently Asked Questions
Amylyx Pharmaceuticals, Inc. (AMLX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
How fast is Amylyx Pharmaceuticals, Inc. growing?
Amylyx Pharmaceuticals, Inc. (AMLX) saw revenue decline by 100.0% over the past year.
Is AMLX profitable?
Amylyx Pharmaceuticals, Inc. (AMLX) reported a net loss of $150.1M for fiscal year 2025.
Dividend & Returns
What is AMLX's return on equity?
Amylyx Pharmaceuticals, Inc. (AMLX) has a return on equity (ROE) of -61.6%. Negative ROE indicates the company is unprofitable.
What is Amylyx Pharmaceuticals, Inc.'s free cash flow?
Amylyx Pharmaceuticals, Inc. (AMLX) had negative free cash flow of $120.5M in fiscal year 2025, likely due to heavy capital investments.